Resistance Mechanisms to AZD9291 and Rociletinib-Response.

08:00 EDT 15th July 2017 | BioPortfolio

Summary of "Resistance Mechanisms to AZD9291 and Rociletinib-Response."

No Summary Available


Journal Details

This article was published in the following journal.

Name: Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1078-0432
Pages: 3967-3968


DeepDyve research library

PubMed Articles [17842 Associated PubMed Articles listed on BioPortfolio]

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.

AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. Furthermore, AZD9291 is now being evaluate...

AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells.

AZD9291, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is highly selective against EGFR T790M-mutant non-small cell lung cancer (NSCLC). On investigating th...

Metformin synergistically enhances the antitumor activity of the third- generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling.

Third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), rociletinib(CO-1686), is great efficacy against EGFR-mutated patients bearing the T790M resistance ...

Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo.

This study aims to develop new nanoformulations of EGFR T790M targeted inhibitor AZD9291 and paclitaxel (PTX) for combination therapy of lung cancer.

Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus: A review.

The treatment of systemic lupus erythematosus (SLE) with glucocorticoids (GCs) is quite effective; however, GC resistance or insensitivity is a major barrier to the treatment of SLE. Therefore, it is ...

Clinical Trials [6324 Associated Clinical Trials listed on BioPortfolio]

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

Though patients whose tumors harbor EGFR T790M mutation appear to benefit from rociletinib, there is a need to understand the molecular mechanisms that lead to primary and acquired resista...

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

AZD9291 is an oral potent irreversible EGFR TKI selective for sensitizing EGFR mutation and T790M resistance mutation but sparing wild-type EGFR. Preclinical studies indicate that AZD9291 ...

TIGER 1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

The purpose of this study is to compare the safety and anti-tumor effect of rociletinib with erlotinib, another EGFR TKI drug, in patients whose tumors have specific EGFR mutations and who...

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with one of either MEDI4736, AZD6094 OR selumetinib i...

An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer

AZD9291 Early Access Program (EAP) was available in Taiwan during October 2015 to September 2016, a time period before the approval of AZD9291, to supply the unlicensed AZD9291 for the NSC...

Medical and Biotech [MESH] Definitions

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Nonsusceptibility of bacteria to the action of the beta-lactam antibiotics. Mechanisms responsible for beta-lactam resistance may be degradation of antibiotics by BETA-LACTAMASES, failure of antibiotics to penetrate, or low-affinity binding of antibiotics to targets.

A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.

Diminished or failed response of PLANTS to HERBICIDES.

The observable response made to a situation and the unconscious processes underlying it.

Quick Search


DeepDyve research library

Searches Linking to this Article